cetylpyridinium chloride anhydrous has been researched along with thromboxanes in 1 studies
| Timeframe | Studies, this research(%) | All Research% |
|---|---|---|
| pre-1990 | 0 (0.00) | 18.7374 |
| 1990's | 0 (0.00) | 18.2507 |
| 2000's | 1 (100.00) | 29.6817 |
| 2010's | 0 (0.00) | 24.3611 |
| 2020's | 0 (0.00) | 2.80 |
| Authors | Studies |
|---|---|
| Cockcroft, JR; Coffey, MJ; Coles, B; Lewis, MJ; Morrow, JD; O'Donnell, VB; Sanchez, S; Williams, PC | 1 |
1 trial(s) available for cetylpyridinium chloride anhydrous and thromboxanes
| Article | Year |
|---|---|
In vivo aspirin supplementation inhibits nitric oxide consumption by human platelets.
Topics: Aspirin; Blood Platelets; Cyclic GMP; Dose-Response Relationship, Drug; Health; Humans; Isoenzymes; Nitric Oxide; Platelet Aggregation; Prostaglandin-Endoperoxide Synthases; Thromboxanes; Time Factors | 2005 |